Form 4: Inmune Bio Director Scott Juda Acquires 32,500 Stock Options

Inmune Bio director Scott Juda was granted 32,500 stock options on December 5, 2024, which will vest in two years.

Summary

• Scott Juda, a director at Inmune Bio, Inc., was granted 32,500 stock options on December 5, 2024.
• The options have an exercise price of $5.05 per share.
• These options were granted under the company's 2021 Stock Incentive Plan.
• The options will fully vest and become exercisable on December 5, 2026, which is two years after the grant date.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock options to a director, which is generally viewed positively as it aligns interests. There is no indication of any negative sentiment.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting period of two years encourages long-term commitment from the director.

Industry Context

This is a standard practice for incentivizing directors and aligning their interests with the company's performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in the biotechnology sector.
• The vesting period of two years is also typical, designed to encourage long-term commitment and performance.

Stakeholder Impact

• The grant of stock options to a director can be seen positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, equity, Inmune Bio, INMB, director, Scott Juda